Skip to main content
Log in

Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis

  • Systematic Review
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Objective

The objective of this systematic review was to compare the efficacy and safety of tacrolimus with cyclophosphamide in primary membranous nephropathy (PMN) patients.

Data Sources and Study Eligibility Criteria

We conducted a literature search in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CCRCT). Any study that compared the efficacy or safety between tacrolimus and cyclophosphamide in the adult PMN patients was included.

Results

We included four randomized controlled trials and two prospective cohort studies with 389 PMN patients. The pooled results using the Dersimonian and Laird method showed that renal remission rates at the longest follow-up periods were not significantly different between the tacrolimus and cyclophosphamide groups (overall remission, six trials, n = 389, relative risk [RR] 0.994 [95% confidence interval [CI] 0.768–1.286); complete remission, six trials, n = 389, RR 1.256 [95% CI 0.733–2.150]). Further analyses found that tacrolimus was comparable with cyclophosphamide for inducing renal remission within 1 year but inferior to cyclophosphamide after 1-year follow-up. It should be noted that only two studies reported the outcomes after 1-year follow-up, which might be considered as weak evidence. The rates of relapse and the drop-outs due to adverse effects were not significantly different (relapse, six trials, n = 389, RR 2.244 [95% CI 0.892–5.644]; drop-outs, six trials, n = 389, RR 1.330 [95% CI 0.412–4.291]). However, the cyclophosphamide group had a significantly higher risk of leukopenia than the tacrolimus group (four trials, n = 216, RR 0.203 [95% CI 0.045–0.916]), whereas the rates of tremor were significantly higher in the tacrolimus group than in the cyclophosphamide group (three trials, n = 202, RR 8.939 [95% CI 1.694–47.173]).

Limitations

The quality and short follow-up durations of the studies limited the reliability of our conclusions.

Conclusions

Tacrolimus was comparable with cyclophosphamide for inducing renal remission of PMN patients within 1 year, but the long-term effects need to be investigated. The cyclophosphamide group had a significantly higher risk of leukopenia, whereas the tacrolimus group had significantly higher rates of tremor. These conclusions need to be further verified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010;56:157–67.

    Article  PubMed  Google Scholar 

  2. Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27:3739–46. doi:10.1681/ASN.2016010093.

    Article  PubMed  Google Scholar 

  3. Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329:85–9.

    Article  CAS  PubMed  Google Scholar 

  4. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371:2277–87.

    Article  PubMed  PubMed Central  Google Scholar 

  6. van den Brand JAJG, van Dijk PR, Hofstra JM, et al. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9:1066–73.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35:100–5.

    CAS  PubMed  Google Scholar 

  8. Garnock-Jones KP. Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients. Drugs. 2015;75:309–20.

    Article  CAS  PubMed  Google Scholar 

  9. O’Grady JG, Burroughs A, Hardy P, et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360:1119–25.

    Article  PubMed  Google Scholar 

  10. Margreiter R. European Tacrolimus vs Ciclosporin Microemulsion Renal, Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002;359:741–6.

    Article  CAS  PubMed  Google Scholar 

  11. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients—a large European trial. Am J Transplant. 2006;6:1387–97.

    Article  CAS  PubMed  Google Scholar 

  12. Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009;53:760–9.

    Article  CAS  PubMed  Google Scholar 

  13. Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant. 2004;4:937–45.

    Article  CAS  PubMed  Google Scholar 

  14. Yuan H, Liu N, Sun GD, et al. Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. Pharmacology. 2013;91:259–66.

    Article  CAS  PubMed  Google Scholar 

  15. Caro J, Gutiérrez-Solís E, Rojas-Rivera J, et al. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant. 2015;30:467–74.

    Article  PubMed  Google Scholar 

  16. Ramachandran R, Hn HK, Kumar V, et al. Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology (Carlton). 2016;21:139–46.

    Article  CAS  PubMed  Google Scholar 

  17. Ramachandran R, Kumar V, Nada R, et al. Tacrolimus with corticosteroids is inferior to modified Ponticelli regimen in the management of primary membranous nephropathy: results at 2 years of randomization. Nephrol Dialysis Transplant. 2016;31(Suppl 1):i77.

    Google Scholar 

  18. Peng L, Wei SY, Li LT, et al. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. J Formos Med Assoc. 2016;115:11–8.

    Article  PubMed  Google Scholar 

  19. Xu J, Zhang W, Xu Y, et al. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol. 2013;181:152–62.

    Article  PubMed  Google Scholar 

  20. He L, Peng Y, Liu H, et al. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J Nephrol. 2013;26:564–71.

    Article  CAS  PubMed  Google Scholar 

  21. Chen M, Li H, Li XY, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010;339:233–8.

    Article  PubMed  Google Scholar 

  22. Li X, Lv R, He Q, et al. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria. J Nephrol. 2008;21:584–91.

    CAS  PubMed  Google Scholar 

  23. Chen Y, Schieppati A, Chen X, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2014;10:CD004293.

    Google Scholar 

  24. Chen Y, Schieppati A, Cai G, et al. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol. 2013;8:787–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Xie G, Xu J, Ye C, et al. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults. PLoS One. 2012;7:e44330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org. Accessed 20 Mar 2011.

  28. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.

  29. Praga M, Barrio V, Juárez GF, et al. Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71:924–30.

    Article  CAS  PubMed  Google Scholar 

  30. Ballarin J, Poveda R, Ara J, et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant. 2007;22:3196–201.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

No writing assistance was used in the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lin-lin Liu.

Ethics declarations

Conflict of interest

Lin-lin Liu, Lin-bo Zhu, Li Yao, and Li-ning Wang have declared no conflicts of interest.

Funding

This study was supported by the National Natural Science Foundation Young Investigator Grant Program (81500525) and the Natural Science Foundation of Liaoning Province (2014021046).

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 27 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, Lb., Liu, Ll., Yao, L. et al. Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis. Drugs 77, 187–199 (2017). https://doi.org/10.1007/s40265-016-0683-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-016-0683-z

Keywords

Navigation